Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles A Seabury

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
International Urology and Nephrology|April 22, 2026
Clinical significance of the combined systematic 12-core with concomitant MRI image-guided targeted prostate biopsy: can the MRI targeted biopsy stand on its own?Charles A Seabury, Yousif M Shakroo, Dharam M Ramnani, et al.
Pathology, Research and Practice|November 14, 2024
Germline pathogenic variants in prostate cancerYousif M Shakroo, Charles A Seabury, Kenneth A Iczkowski, et al.
The Journal of Urology|June 7, 2002
Evaluation of a new serum testing method for detection of prostate cancerCharles A Seabury, Emanuel Calenoff, Charles Ditlow, et al.
The Journal of Urology|July 6, 2026
Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary DiseaseSam S Chang, Karim Chamie, Charles A Seabury, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
International Urology and Nephrology|April 22, 2026
Clinical significance of the combined systematic 12-core with concomitant MRI image-guided targeted prostate biopsy: can the MRI targeted biopsy stand on its own?Charles A Seabury, Yousif M Shakroo, Dharam M Ramnani, et al.
Pathology, Research and Practice|November 14, 2024
Germline pathogenic variants in prostate cancerYousif M Shakroo, Charles A Seabury, Kenneth A Iczkowski, et al.
The Journal of Urology|June 7, 2002
Evaluation of a new serum testing method for detection of prostate cancerCharles A Seabury, Emanuel Calenoff, Charles Ditlow, et al.
The Journal of Urology|July 6, 2026
Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary DiseaseSam S Chang, Karim Chamie, Charles A Seabury, et al.
Pageof 1